Nephrogenic fibrosing dermopathy

Revision as of 15:05, 28 September 2012 by Aarti Narayan (talk | contribs)
Jump to navigation Jump to search

Nephrogenic fibrosing dermopathy Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nephrogenic fibrosing dermopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nephrogenic fibrosing dermopathy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nephrogenic fibrosing dermopathy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nephrogenic fibrosing dermopathy

CDC on Nephrogenic fibrosing dermopathy

Nephrogenic fibrosing dermopathy in the news

Blogs on Nephrogenic fibrosing dermopathy

Directions to Hospitals Treating Nephrogenic fibrosing dermopathy

Risk calculators and risk factors for Nephrogenic fibrosing dermopathy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assistant Editor-in-Chief: Brian Blank

Synonyms and keywords: nephrogenic systemic fibrosis

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nephrogenic fibrosing dermopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination | Laboratory Findings | X-Ray | CT | MRI | Echocardiogram or Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Source



de:Nephrogene systemische Fibrose Template:WH Template:WS